

"TEMPUS

Tempus Announces Second Sequencing Collaboration with Lilly to Expand Patient Access to Genomic Testing

April 3, 2023

Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration sponsored by Eli Lilly and Company designed to expand access to genomic testing for eligible patients who have advanced or metastatic medullary thyroid cancer (MTC) OR advanced or metastatic non-medullary thyroid cancer (non-MTC). This collaboration offers Tempus' molecular profiling offerings at no cost while simultaneously working with physicians to support them in providing data-driven treatment to their patients with the use of broad-panel genomic testing. This collaboration builds upon the initial partnership with Lilly announced in June 2022 focused on providing broader access to genomic testing for patients with advanced/metastatic non-small cell lung cancer.

"We are looking forward to expanding our work with Lilly in broadening access to genomic sequencing and assisting physicians in determining the best, data-driven treatment plan for their patients," said Michael Yasjejko, Executive Vice President at Tempus. "We've started to see the impact of our program through our first collaboration with Lilly in non-small cell lung cancer, and are excited to expand our work into thyroid cancer – another cancer type in which increased genomic testing will positively impact both physicians and patients."

Tempus' signature xT assay has the capability to detect all four types of genomic alterations identified by NCCN Guidelines®. Physicians have the option of using Tempus' xT assay for their patients, which is designed to detect actionable alterations by sequencing tumor samples with matched normal saliva or blood samples. In cases where a patient's tissue is unavailable or is not sufficient to conduct broad-based tissue testing, Tempus' xF liquid biopsy assay is available as an alternative. To learn more, visit [here](#).

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.